Literature DB >> 27636408

Increased Prevalence of Metabolic Risk Factors in Asian Americans With Hepatocellular Carcinoma.

Alina Kutsenko1, Maya R Ladenheim, Nathan Kim, Pauline Nguyen, Vincent Chen, Channa Jayasekera, Ju Dong Yang, Radhika Kumari, Lewis Roberts, Mindie H Nguyen.   

Abstract

BACKGROUND: We used metabolic risk factors to estimate the prevalence and clinical significance of nonalcoholic fatty liver disease in Asian Americans with hepatocellular carcinoma (HCC).
METHODS: This is a retrospective cohort study of 824 consecutive Asian HCC patients at Stanford University Medical Center from 1998 to 2015. Patients were subdivided as: Chinese, other East Asian (Japanese and Korean), South East Asian (Vietnamese, Thai, and Laotian), Maritime South East Asian (MSEA: Malaysian, Indonesian, Filipino, and Singaporean), and South West Asian (Indian, Pakistani, and Middle Eastern). Metabolic risk factors studied were body mass index, hypertension, type II diabetes, and hyperlipidemia.
RESULTS: Most patients were male (76%) with mean age 63 years. Metabolic risk factors were highly prevalent on presentation and increased over time (P<0.001), as did the prevalence of cryptogenic HCC (P<0.004). Compared with other Asian subgroups, MSEAs had the highest body mass index (26.3) and higher rates of type II diabetes (44% vs. 23% to 35%, P=0.004), hypertension (59% vs. 38% to 55%, P=0.04), and cryptogenic HCC (15% vs. 4% to 10%, P=0.01). They were more likely to be symptomatic on presentation (44% vs. 32% to 58%, P=0.07), less likely to present within Milan criteria (34% vs. 35% to 63%, P<0.0001), and trended toward decreased 10-year survival rates compared with other ethnic subgroups (9% vs. 25% to 32%, P=0.07).
CONCLUSIONS: Metabolic risk factors were increasingly prevalent among Asian Americans with HCC. MSEAs, who had the highest incidence of these risk factors, had more advanced tumor stage and trended toward worse survival.

Entities:  

Mesh:

Year:  2017        PMID: 27636408     DOI: 10.1097/MCG.0000000000000689

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  4 in total

1.  Patterns and co-occurrence of risk factors for hepatocellular carcinoma in four Asian American communities: a cross-sectional study.

Authors:  Susan L Stewart; Julie Ht Dang; Natalie J Török; Moon S Chen
Journal:  BMJ Open       Date:  2019-06-28       Impact factor: 2.692

2.  Prediction of hepatocellular carcinoma risk in patients with type-2 diabetes using supervised machine learning classification model.

Authors:  Noor Atika Azit; Shahnorbanun Sahran; Voon Meng Leow; Manisekar Subramaniam; Suryati Mokhtar; Azmawati Mohammed Nawi
Journal:  Heliyon       Date:  2022-09-29

3.  Gastrin inhibits gastric cancer progression through activating the ERK-P65-miR23a/27a/24 axis.

Authors:  Li-Dong Zu; Xing-Chun Peng; Zhi Zeng; Jing-Long Wang; Li-Li Meng; Wei-Wei Shen; Chun-Ting Hu; Ye Yang; Guo-Hui Fu
Journal:  J Exp Clin Cancer Res       Date:  2018-06-04

Review 4.  Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities.

Authors:  Nikolaos Garmpis; Christos Damaskos; Anna Garmpi; Vasiliki E Georgakopoulou; Panagiotis Sarantis; Efstathios A Antoniou; Michalis V Karamouzis; Afroditi Nonni; Dimitrios Schizas; Evangelos Diamantis; Evangelos Koustas; Paraskevi Farmaki; Athanasios Syllaios; Alexandros Patsouras; Konstantinos Kontzoglou; Nikolaos Trakas; Dimitrios Dimitroulis
Journal:  J Pers Med       Date:  2021-03-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.